Skip to main content
  • Meeting abstract
  • Published:

Serum S100 as a marker of cerebral injury in acute liver failure (ALF) and during orthotopic liver transplantation (OLT)

Introduction

Encephalopathy and irreversible cerebral injury may occur in ALF. S100 is a CNS-specific protein that is a marker of cerebral injury [1,2]. We investigated S100 protein in patients with ALF who underwent OLT.

Methods

After IRB approval blood samples were taken in 10 patients age 20-51 years with ALF. Blood was taken before OLT (A), during the anhepatic phase (B), 30 min after reperfusion (C), and on days 1 (D) and 4 (E) post-OLT. The blood was centrifuged and serum stored at -70°C. S100 was analysed using an immunoluminometric assay.

Results

Serum S100 (X ± SEM) was elevated prior to OLT (normal < 0.12 µg/l). By day 4 post-OLT S100 had fallen in all patients except one. This patient subsequently died.

figure 1

Conclusion

Serum S100 is elevated in ALF and encephalopathy. We observed a rise in S100 during OLT in these patients. The role of S100 as a marker of neuronal injury in ALF and OLT warrants further investigation.

References

  1. Stroke 1997, 28: 1956.

  2. Ann Clin Biochem 1997, 34: 546-550.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leonard, S., Watts, A., Parmar, K. et al. Serum S100 as a marker of cerebral injury in acute liver failure (ALF) and during orthotopic liver transplantation (OLT). Crit Care 3 (Suppl 1), P223 (2000). https://doi.org/10.1186/cc596

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/cc596

Keywords